Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus
NCT ID: NCT01460888
Last Updated: 2013-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
36 participants
INTERVENTIONAL
2013-07-31
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OLA-0 (de-escalation dose)
25mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
Olaparib
25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
Radical external beam radiotherapy, 50Gy in 25 fractions
Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
OLA-1
50mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
Olaparib
25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
Radical external beam radiotherapy, 50Gy in 25 fractions
Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
OLA-2
100mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
Olaparib
25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
Radical external beam radiotherapy, 50Gy in 25 fractions
Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
OLA-3
200mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
Olaparib
25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
Radical external beam radiotherapy, 50Gy in 25 fractions
Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
RT alone
Radical external beam radiotherapy, 50Gy in 25 fractions
Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olaparib
25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
Radical external beam radiotherapy, 50Gy in 25 fractions
Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Unsuitable for radical chemoradiation therapy but suitable for radiotherapy
3. Total length of tumour and involved lymph nodes ≤10cm
4. No oesophageal stent in situ
5. No previous chemotherapy or radiotherapy for oesophagus cancer
6. Disease which can be encompassed within a radical radiotherapy treatment volume
7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (see ECOG criteria appendix 1)
8. Provision of fully informed consent, signed, written and dated, prior to any study specific procedures.
9. \> 18 years of age.
10. Adequate organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:
* Haemoglobin ≥ 10.0 g/dL
* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
* White blood cells (WBC) \> 3 x 109/L
* Platelet count ≥ 100 x 109/L
* No dysplastic features on peripheral blood smear
* Total bilirubin ≤ 1.5 x institutional upper limit of normal
* Aspartate aminotransferase (AST(SGOT)/Alanine transaminase (ALT)SGPT) ≤ 2.5 x institutional upper limit of normal
* Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN)
11. Adequate lung function: no history of interstitial lung disease and FEV1 \> 1litre and \>30% predicted.
12. Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1. Postmenopausal is defined as:
* Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
* Luteinizing hormone(LH) and Follicle-stimulating hormone (FSH) levels in the post menopausal range for women under 50,
* radiation-induced oophorectomy with last menses \>1 year ago,
* chemotherapy-induced menopause with \>1 year interval since last menses,
* surgical sterilisation (bilateral oophorectomy or hysterectomy).
13. Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
14. Fit to receive all study treatments
15. Swallowing sufficiently good to tolerate oral medication
16. Life expectancy ≥ 4 months.
Exclusion Criteria
2. Previous enrolment in the present study
3. Treatment with any investigational product during the last 14 days (or a longer period depending on the defined characteristics of the agents used)
4. Any previous treatment with a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, including olaparib.
5. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years.
6. Patients receiving the following classes of inhibitors of cytochrome P450 3A4 (CYP3A4)
* Azole antifungals
* Macrolide antibiotics
* Protease inhibitors
7. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
8. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, or any psychiatric disorder that prohibits obtaining informed consent.
9. Patients with a history of interstitial lung disease, inflammatory lung conditions, or severe chronic obstructive pulmonary disease (COPD) (FEV1\<1litre or \< 30% predicted). Patients with pneumonia within the previous 3 months.
10. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
11. Patients with oesophageal stent in-situ
12. Patients with myelodysplastic syndrome/acute myeloid leukaemia
13. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).
14. Patients with known active hepatic disease (i.e., Hepatitis B or C).
15. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
16. Patients with uncontrolled seizures.
17. Concurrent uncontrolled medical illness, or other previous or current malignant disease likely to interfere with protocol treatments / comparisons
18. Age \< 18
19. Any pregnant, lactating women or potentially childbearing patients not using adequate contraception (see section 3.4 for details of required contraception).
20. Previous chemotherapy or radiotherapy for oesophageal cancer
21. Metastatic disease apart from local lymph node disease which can be reasonably encompassed within the radiotherapy volume (total length of tumour and lymph node disease should be \<10cm)
22. ECOG performance status \>2
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Research UK
OTHER
AstraZeneca
INDUSTRY
The Christie NHS Foundation Trust
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Jackson, Dr
Role: PRINCIPAL_INVESTIGATOR
University Hospital Southampton NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Southampton General Hospital
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Andrew Jackson, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10_DOG03_194
Identifier Type: -
Identifier Source: org_study_id